KAM
MNTA

Kazazian Asset Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Kazazian Asset Management’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-35,277
Closed -$536K – 116
2015
Q1 		$536K Sell
35,277
-95,597
-73% -$1.24M 0.7% 27
2014
Q4 		$1.58M Buy
+130,874
New +$1.5M 1.37% 18

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kazazian Asset Management's MNTA Position: Q2 2015 in Review

Kazazian Asset Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q2 2015, closing a stake of 35,277 shares — an estimated $536K sold.

Kazazian Asset Management first reported a position in MNTA in Q4 2014 and held it in 2 quarters. The position peaked at $1.58M in Q4 2014. 162 funds tracked by Wall St. Rank hold MNTA as of Q2 2015.

  • Kazazian Asset Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Kazazian Asset Management sold 35,277 Momenta Pharmaceuticals, Inc. shares in Q2 2015, an estimated $536K.
  • Kazazian Asset Management first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
  • Kazazian Asset Management's Momenta Pharmaceuticals, Inc. position peaked at $1.58M in Q4 2014.
  • 162 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q2 2015.

Based on Kazazian Asset Management's 13F filing for Q2 2015, filed 13 Aug 2015.